Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

bioclusters

- PMLiVE

Teva’s generic Nexium wins US approval

FDA backs copy of AstraZeneca’s heartburn drug

- PMLiVE

MedImmune partners with US National Cancer Institute

Will research immunotherapies, imaging and stem cell treatments

- PMLiVE

AZ signs yet another cancer immunotherapy deal

Will work with Omnis to develop viruses that target tumour cells

- PMLiVE

FDA approved 44 new drugs in 2014

AstraZeneca leads pharma success with four approvals, but Bayer had a year to forget  

- PMLiVE

AZ and Cancer Research UK to collaborate on new medicines

Charity’s scientists to be given access to pharma company’s molecule library

- PMLiVE

Amgen/AZ confirm brodalumab psoriasis filing in 2015

Drug demonstrates greater effectiveness than J&J’s Stelara

- PMLiVE

AZ seeks leg up in antiplatelet market with Brilinta antidote

Reversal agent has been developed by company's biotech subsidiary Medimmune

- PMLiVE

Nexium windfall lifts AZ in third quarter

Still to feel effects of generic competition

- PMLiVE

AZ advances immuno-oncology ambitions

Buys imaging company and signs PD-1 collaborations with Pharmacyclics and J&J

- PMLiVE

AZ to work with UK university on drug delivery technologies

Company's staff will also teach parts of courses at The University of Manchester

- PMLiVE

Orphan drugs lead CHMP recommendations

Clinuvel's Scenesse is first drug set for European approval to treat rare intolerance to sunlight

AstraZeneca AZ global R&D corporate HQ

AstraZeneca cements links with Cambridge University

Agrees a series of collaborations in areas such as Alzheimer's and multiple sclerosis

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links